Ask AI

ISLEND-2: Quality of Life in People With Virologically Suppressed HIV After Switch to Weekly ISL/LEN

Conference Coverage Slideset
Conference Coverage Slideset Start Activity

Released: November 13, 2026

See Activity Collection

In this assessment of participants in the phase III open-label ISLEND-2 study, investigators used descriptive statistics and validated and de novo questionnaires to evaluate quality of life in persons with virologically suppressed HIV who switched from daily oral standard-of-care ART to once-weekly islatravir/lenacapavir. 

ISLEND-2 QoL

Activity Information

Released: November 13, 2026